Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

Abstract excerpt

BACKGROUND: Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD). METHODS: In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of exacerbations, and a blood eosinophil count of at least 300...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Asthma and respiratory diseases
• Share to Chronic Obstructive Pulmonary Disease (COPD) Research
• Share to Delphi Technique in Research